Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report

Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Masaya, Fujii, Nobuharu, Mizuhara, Kentaro, Urata, Tomohiro, Sumii, Yuichi, Fujiwara, Yuki, Seike, Keisuke, Sando, Yasuhisa, Nakamura, Makoto, Fujii, Keiko, Saeki, Kyosuke, Meguri, Yusuke, Asada, Noboru, Ennishi, Daisuke, Nishimori, Hisakazu, Matsuoka, Ken-ichi, Maeda, Yoshinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111671/
https://www.ncbi.nlm.nih.gov/pubmed/34007785
http://dx.doi.org/10.1016/j.lrr.2021.100241
_version_ 1783690550085419008
author Abe, Masaya
Fujii, Nobuharu
Mizuhara, Kentaro
Urata, Tomohiro
Sumii, Yuichi
Fujiwara, Yuki
Seike, Keisuke
Sando, Yasuhisa
Nakamura, Makoto
Fujii, Keiko
Saeki, Kyosuke
Meguri, Yusuke
Asada, Noboru
Ennishi, Daisuke
Nishimori, Hisakazu
Matsuoka, Ken-ichi
Maeda, Yoshinobu
author_facet Abe, Masaya
Fujii, Nobuharu
Mizuhara, Kentaro
Urata, Tomohiro
Sumii, Yuichi
Fujiwara, Yuki
Seike, Keisuke
Sando, Yasuhisa
Nakamura, Makoto
Fujii, Keiko
Saeki, Kyosuke
Meguri, Yusuke
Asada, Noboru
Ennishi, Daisuke
Nishimori, Hisakazu
Matsuoka, Ken-ichi
Maeda, Yoshinobu
author_sort Abe, Masaya
collection PubMed
description Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development.
format Online
Article
Text
id pubmed-8111671
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81116712021-05-17 Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report Abe, Masaya Fujii, Nobuharu Mizuhara, Kentaro Urata, Tomohiro Sumii, Yuichi Fujiwara, Yuki Seike, Keisuke Sando, Yasuhisa Nakamura, Makoto Fujii, Keiko Saeki, Kyosuke Meguri, Yusuke Asada, Noboru Ennishi, Daisuke Nishimori, Hisakazu Matsuoka, Ken-ichi Maeda, Yoshinobu Leuk Res Rep Article Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development. Elsevier 2021-04-22 /pmc/articles/PMC8111671/ /pubmed/34007785 http://dx.doi.org/10.1016/j.lrr.2021.100241 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Abe, Masaya
Fujii, Nobuharu
Mizuhara, Kentaro
Urata, Tomohiro
Sumii, Yuichi
Fujiwara, Yuki
Seike, Keisuke
Sando, Yasuhisa
Nakamura, Makoto
Fujii, Keiko
Saeki, Kyosuke
Meguri, Yusuke
Asada, Noboru
Ennishi, Daisuke
Nishimori, Hisakazu
Matsuoka, Ken-ichi
Maeda, Yoshinobu
Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
title Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
title_full Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
title_fullStr Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
title_full_unstemmed Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
title_short Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
title_sort total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: a case report
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111671/
https://www.ncbi.nlm.nih.gov/pubmed/34007785
http://dx.doi.org/10.1016/j.lrr.2021.100241
work_keys_str_mv AT abemasaya totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT fujiinobuharu totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT mizuharakentaro totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT uratatomohiro totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT sumiiyuichi totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT fujiwarayuki totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT seikekeisuke totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT sandoyasuhisa totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT nakamuramakoto totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT fujiikeiko totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT saekikyosuke totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT meguriyusuke totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT asadanoboru totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT ennishidaisuke totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT nishimorihisakazu totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT matsuokakenichi totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport
AT maedayoshinobu totalbodyirradiationbasedhaploidenticalhematopoieticstemcelltransplantationusingposttransplantcyclophosphamideafteradministrationofinotuzumabozogamicinacasereport

Ejemplares similares